Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01965652
Registration number
NCT01965652
Ethics application status
Date submitted
15/10/2013
Date registered
18/10/2013
Date last updated
18/04/2018
Titles & IDs
Public title
Long Term Safety of Naldemedine
Query!
Scientific title
A Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study to Evaluate the Long-term Safety of Naldemedine for the Treatment of Opioid-induced Constipation in Subjects With Non-malignant Chronic Pain Receiving Opioid Therapy
Query!
Secondary ID [1]
0
0
1326V9235
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Opioid-induced Constipation
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Mental Health
0
0
0
0
Query!
Addiction
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Naldemedine
Treatment: Drugs - Placebo
Experimental: Naldemedine - Participants received 0.2 mg naldemedine tablets orally once daily for 52 weeks.
Placebo comparator: Placebo - Participants received matching placebo tablets orally once daily for 52 weeks.
Treatment: Drugs: Naldemedine
Naldemedine 0.2 mg tablet taken orally once a day
Treatment: Drugs: Placebo
Placebo tablet taken orally once a day
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Adverse Events
Query!
Assessment method [1]
0
0
A serious adverse event was defined as any adverse event (AE) that resulted in any of the following outcomes: death, life-threatening AE, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life threatening, or require hospitalization were considered an SAE when, based upon appropriate medical judgment, they jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above.
Adverse drug reactions (ADRs) were defined as adverse events that were considered by the investigator to be definitely, probably, or possibly related to study drug. Serious ADRs were defined as serious AEs considered by the investigator to be definitely, probably, or possibly related to study drug.
Query!
Timepoint [1]
0
0
From the first dose of study drug up to 14 days after the last dose of study drug (54 weeks).
Query!
Secondary outcome [1]
0
0
Change From Baseline in the Number of Bowel Movements Per Week
Query!
Assessment method [1]
0
0
Participants monitored their bowel movements and completed a daily bowel habits diary the week prior to study visits (i.e. during Weeks 11, 23, 35, and 51).
Query!
Timepoint [1]
0
0
Baseline and Weeks 12, 24, 36, and 52
Query!
Secondary outcome [2]
0
0
Percentage of Participants Meeting Each Criterion of Laxative Use
Query!
Assessment method [2]
0
0
Participants who were taking stable routine/regular laxatives at Screening were to continue taking the same regimen throughout the study.
The percentage of participants meeting each of the criteria below are reported:
1. Participants not on stable laxatives, defined as participants who did not use laxatives from 28 days prior to the Screening Period to the final dose of study drug or who received only rescue laxative. Rescue is defined as any laxative taken for the first time during the Treatment Period.
1a. Out of participants who were not on stable laxatives, participants who received rescue laxatives.
2. Participants on stable laxatives, defined as participants who may have had at least one/any stable laxative use reported from 28 days prior to Screening Period to the final dose of study drug.
2a. Out of participants who were on stable laxatives, participants who received rescue laxatives.
3. Participants who did not meet criteria 1 or 2.
Query!
Timepoint [2]
0
0
From 28 days prior to screening until the end of the treatment period (total of 56 weeks)
Query!
Secondary outcome [3]
0
0
Change From Baseline in the Overall Score for Patient Assessment of Constipation Symptoms
Query!
Assessment method [3]
0
0
The Patient Assessment of Constipation Symptom Questionnaire (PAC-SYM) asked participants to rate the severity of 12 constipation symptoms in the last 2 weeks on a scale from 0 (absent) to 4 (very severe). The overall score was calculated as the mean of all 12 items and ranges from 0 (best) to 4 (worst). A negative change from baseline value indicates improvement.
Query!
Timepoint [3]
0
0
Baseline and Weeks 2, 12, 24, 36, and 52
Query!
Secondary outcome [4]
0
0
Change From Baseline in the PAC-SYM Abdominal-symptoms Domain Score
Query!
Assessment method [4]
0
0
The Patient Assessment of Constipation Symptom Questionnaire (PAC-SYM) asked participants to rate the severity of 12 constipation symptoms in the last 2 weeks on a scale from 0 (absent) to 4 (very severe). The abdominal-symptom domain score was calculated as the mean of the following 4 items: abdominal discomfort, abdominal pain, abdominal bloating and stomach cramps.
A negative change from baseline value indicates improvement in symptoms.
Query!
Timepoint [4]
0
0
Baseline and Weeks 2, 12, 24, 36, and 52
Query!
Secondary outcome [5]
0
0
Change From Baseline in the PAC-SYM Rectal-symptoms Domain Score
Query!
Assessment method [5]
0
0
The Patient Assessment of Constipation Symptom Questionnaire (PAC-SYM) asked participants to rate the severity of 12 constipation symptoms in the last 2 weeks on a scale from 0 (absent) to 4 (very severe). The abdominal-symptom domain score was calculated as the mean of the following 3 items: painful bowel movements, rectal burning during or after a bowel movement, and rectal bleeding or tearing during or after a bowel movement. A negative change from baseline value indicates improvement in symptoms.
Query!
Timepoint [5]
0
0
Baseline and Weeks 2, 12, 24, 36, and 52
Query!
Secondary outcome [6]
0
0
Change From Baseline in the PAC-SYM Stool-symptoms Domain Score
Query!
Assessment method [6]
0
0
The Patient Assessment of Constipation Symptom Questionnaire (PAC-SYM) asked participants to rate the severity of 12 constipation symptoms in the last 2 weeks on a scale from 0 (absent) to 4 (very severe). The stool-symptom domain score was calculated as the mean of the following 5 items: incomplete bowel movements, bowel movements that were too hard, bowel movements that were too small, straining or squeezing to try to pass bowel movements, and false-alarm bowel movements.
A negative change from baseline value indicates improvement in symptoms.
Query!
Timepoint [6]
0
0
Baseline and Weeks 2, 12, 24, 36, and 52
Query!
Secondary outcome [7]
0
0
Change From Baseline in the Patient Assessment of Constipation Quality of Life Overall Score
Query!
Assessment method [7]
0
0
The Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) consists of 28 questions designed to measure the impact constipation has had on participants' daily life during the past 2 weeks.
Each question was evaluated by the participant on a five-point scale ranging from 0 (not at all or none of the time) to 4 (extremely or all of the time), where higher scores represent poorer quality of life. The overall score was calculated as the mean of all 28 item scores. A negative change from baseline value indicates improvement.
Query!
Timepoint [7]
0
0
Baseline and Weeks 2, 12, 24, 36, and 52
Query!
Secondary outcome [8]
0
0
Change From Baseline in the Physical Discomfort Domain of PAC-QOL
Query!
Assessment method [8]
0
0
The Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) consists of 28 questions designed to measure the impact constipation has had on participants' daily life during the past 2 weeks.
Each question was evaluated by the participant on a five-point scale ranging from 0 (not at all or none of the time) to 4 (extremely or all of the time), where higher scores represent poorer quality of life. The physical discomfort domain consists of 4 questions related to bloating, feeling heavy, how much of the time participants felt any physical discomfort and how much time they felt the need to open their bowel but were not able to. The physical discomfort score was calculated as the mean of the 4 individual scores. A negative change from baseline value indicates improvement.
Query!
Timepoint [8]
0
0
Baseline and Weeks 2, 12, 24, 36, and 52
Query!
Secondary outcome [9]
0
0
Change From Baseline in the Psychosocial Discomfort Domain of PAC-QOL
Query!
Assessment method [9]
0
0
The Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) consists of 28 questions designed to measure the impact constipation has had on participants' daily life during the past 2 weeks.
Each question was evaluated by the participant on a five-point scale ranging from 0 (not at all or none of the time) to 4 (extremely or all of the time), where higher scores represent poorer quality of life. The psychosocial discomfort domain consists of 8 questions related to participants' embarrassment regarding their constipation and effects of constipation on eating habits and appetite.
The psychosocial discomfort score was calculated as the mean of the 8 individual scores. A negative change from baseline value indicates improvement.
Query!
Timepoint [9]
0
0
Baseline and Weeks 2, 12, 24, 36, and 52
Query!
Secondary outcome [10]
0
0
Change From Baseline in the Worries and Concerns Domain of PAC-QOL
Query!
Assessment method [10]
0
0
The Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) consists of 28 questions designed to measure the impact constipation has had on participants' daily life during the past 2 weeks.
Each question was evaluated by the participant on a five-point scale ranging from 0 (not at all or none of the time) to 4 (extremely or all of the time), where higher scores represent poorer quality of life. The worries and concerns domain consists of 11 questions related to participants' feelings and concerns about their constipation. The worries and concerns domain score was calculated as the mean of the 11 individual scores. A negative change from baseline value indicates improvement.
Query!
Timepoint [10]
0
0
Baseline and Weeks 2, 12, 24, 36, and 52
Query!
Secondary outcome [11]
0
0
Change From Baseline in the Satisfaction Domain of PAC-QOL
Query!
Assessment method [11]
0
0
The Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) consists of 28 questions designed to measure the impact constipation has had on participants' daily life during the past 2 weeks.
Each question was evaluated by the participant on a five-point scale ranging from 0 (not at all or none of the time) to 4 (extremely or all of the time), where higher scores represent poorer quality of life. The satisfaction domain consists of 5 questions related to participants' feelings of satisfaction with their bowel function. The satisfaction domain score was calculated as the mean of the 5 individual scores. A negative change from baseline value indicates improvement.
Query!
Timepoint [11]
0
0
Baseline and Weeks 2, 12, 24, 36, and 52
Query!
Secondary outcome [12]
0
0
Participant Global Satisfaction
Query!
Assessment method [12]
0
0
Participants were asked to rate their degree of satisfaction of constipation and abdominal symptoms from the start of study drug dosing to Week 52 (or early termination).
Satisfaction was rated based on the following seven grades:
* Grade 1 = markedly worsened
* Grade 2 = moderately worsened
* Grade 3 = slightly worsened
* Grade 4 = unchanged
* Grade 5 = slightly improved
* Grade 6 = moderately improved
* Grade 7 = markedly improved
Query!
Timepoint [12]
0
0
Week 52 or early termination visit
Query!
Eligibility
Key inclusion criteria
Inclusion Criteria
1. Subjects aged 18 to 80 years inclusive at the time of informed consent
2. Subjects must have non-malignant chronic pain treated and must have opioid induced constipation (OIC)
3. Subjects must be treated with a stable opioid regimen at a total daily dose on average of = 30 mg equivalents of oral morphine sulfate
4. Subjects may or may not be on a routine laxative regimen at the time of Screening
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria
1. Evidence of significant structural abnormalities of the gastrointestinal (GI) tract
2. Evidence of active medical diseases affecting bowel transit
3. History of pelvic disorders that may be a cause of constipation
4. Surgery (except for minor procedures) within 60 days of Screening
5. History of chronic constipation prior to starting analgesic medication or any potential non-opioid cause of bowel dysfunction that may be a major contributor to the constipation (e.g. mechanical GI obstruction)
6. Subjects who have never taken laxatives for the treatment of OIC
7. Current use of any prohibited medication including opioid antagonists, partial or mixed agonists/antagonists
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
24/09/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
12/01/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1246
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Shionogi Research Site - Adelaide
Query!
Recruitment hospital [2]
0
0
Shionogi Research Site - Bedford Park
Query!
Recruitment hospital [3]
0
0
Shionogi Research Site - Camperdown
Query!
Recruitment hospital [4]
0
0
Shionogi Research Site - Carina Heights
Query!
Recruitment hospital [5]
0
0
Shionogi Research Site - Caulfield South
Query!
Recruitment hospital [6]
0
0
Shionogi Research Site - Malvern East
Query!
Recruitment hospital [7]
0
0
Shionogi Research Site - Nambour
Query!
Recruitment hospital [8]
0
0
Shionogi Research Site - Sherwood
Query!
Recruitment hospital [9]
0
0
Shionogi Research Site - St Leonards
Query!
Recruitment postcode(s) [1]
0
0
- Adelaide
Query!
Recruitment postcode(s) [2]
0
0
- Bedford Park
Query!
Recruitment postcode(s) [3]
0
0
- Camperdown
Query!
Recruitment postcode(s) [4]
0
0
- Carina Heights
Query!
Recruitment postcode(s) [5]
0
0
- Caulfield South
Query!
Recruitment postcode(s) [6]
0
0
- Malvern East
Query!
Recruitment postcode(s) [7]
0
0
- Nambour
Query!
Recruitment postcode(s) [8]
0
0
- Sherwood
Query!
Recruitment postcode(s) [9]
0
0
- St Leonards
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Idaho
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kansas
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kentucky
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Louisiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Massachusetts
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Michigan
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Mississippi
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Nebraska
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Nevada
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New Jersey
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New Mexico
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
New York
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
North Carolina
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Ohio
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Oklahoma
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Oregon
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Pennsylvania
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
South Carolina
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Tennessee
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Texas
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Utah
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Virginia
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Washington
Query!
Country [32]
0
0
Austria
Query!
State/province [32]
0
0
Linz
Query!
Country [33]
0
0
Austria
Query!
State/province [33]
0
0
Vienna
Query!
Country [34]
0
0
Austria
Query!
State/province [34]
0
0
Zams
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
London
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Mirabel
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Sarnia
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
Sherbrooke
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Toronto
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
Vancouver
Query!
Country [41]
0
0
Czechia
Query!
State/province [41]
0
0
Benesov
Query!
Country [42]
0
0
Czechia
Query!
State/province [42]
0
0
Olomouc
Query!
Country [43]
0
0
Czechia
Query!
State/province [43]
0
0
Ostrava
Query!
Country [44]
0
0
Czechia
Query!
State/province [44]
0
0
Pardubice
Query!
Country [45]
0
0
Czechia
Query!
State/province [45]
0
0
Pribram V- Zdabor
Query!
Country [46]
0
0
Denmark
Query!
State/province [46]
0
0
Glostrup
Query!
Country [47]
0
0
Denmark
Query!
State/province [47]
0
0
Hellerup
Query!
Country [48]
0
0
Denmark
Query!
State/province [48]
0
0
Odense
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Soulaine Sur Aubance
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Berlin
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Dresden
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Halle
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Hamburg
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Hannover
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Kassel
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Leipzig
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Luenen
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Mainz
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Muenster
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Stadtroda
Query!
Country [61]
0
0
Hungary
Query!
State/province [61]
0
0
Balatonfuered
Query!
Country [62]
0
0
Hungary
Query!
State/province [62]
0
0
Budapest
Query!
Country [63]
0
0
Hungary
Query!
State/province [63]
0
0
Debrecen
Query!
Country [64]
0
0
Hungary
Query!
State/province [64]
0
0
Hatvan
Query!
Country [65]
0
0
Hungary
Query!
State/province [65]
0
0
Szikszo
Query!
Country [66]
0
0
Israel
Query!
State/province [66]
0
0
Beer Sheva
Query!
Country [67]
0
0
Israel
Query!
State/province [67]
0
0
Haifa
Query!
Country [68]
0
0
Israel
Query!
State/province [68]
0
0
Tel Aviv
Query!
Country [69]
0
0
Israel
Query!
State/province [69]
0
0
Tel Hashomer
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
Asti
Query!
Country [71]
0
0
Italy
Query!
State/province [71]
0
0
Catania
Query!
Country [72]
0
0
Italy
Query!
State/province [72]
0
0
Chieti
Query!
Country [73]
0
0
Italy
Query!
State/province [73]
0
0
Firenze
Query!
Country [74]
0
0
Italy
Query!
State/province [74]
0
0
Napoli
Query!
Country [75]
0
0
Italy
Query!
State/province [75]
0
0
Rionero in Vulture
Query!
Country [76]
0
0
Italy
Query!
State/province [76]
0
0
Roma
Query!
Country [77]
0
0
Italy
Query!
State/province [77]
0
0
Rome
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Chorzów
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Gdansk
Query!
Country [80]
0
0
Poland
Query!
State/province [80]
0
0
Katowice
Query!
Country [81]
0
0
Poland
Query!
State/province [81]
0
0
Lublin
Query!
Country [82]
0
0
South Africa
Query!
State/province [82]
0
0
Alberton
Query!
Country [83]
0
0
South Africa
Query!
State/province [83]
0
0
Lyttelton Centurion
Query!
Country [84]
0
0
South Africa
Query!
State/province [84]
0
0
Muckleneuk Pretoria
Query!
Country [85]
0
0
South Africa
Query!
State/province [85]
0
0
Pretoria West Pretoria
Query!
Country [86]
0
0
South Africa
Query!
State/province [86]
0
0
Worcester
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Barcelona
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Girona
Query!
Country [89]
0
0
Spain
Query!
State/province [89]
0
0
Sevilla
Query!
Country [90]
0
0
Sweden
Query!
State/province [90]
0
0
Skene
Query!
Country [91]
0
0
Sweden
Query!
State/province [91]
0
0
Stockholm
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
Bath
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
Belfast
Query!
Country [94]
0
0
United Kingdom
Query!
State/province [94]
0
0
Bexhill On Sea East Sussex
Query!
Country [95]
0
0
United Kingdom
Query!
State/province [95]
0
0
Chesterfield
Query!
Country [96]
0
0
United Kingdom
Query!
State/province [96]
0
0
Chestfield Kent
Query!
Country [97]
0
0
United Kingdom
Query!
State/province [97]
0
0
Daventry Northants
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
Devon
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
Epworth Doncaster
Query!
Country [100]
0
0
United Kingdom
Query!
State/province [100]
0
0
Harrogate
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
Hinckley
Query!
Country [102]
0
0
United Kingdom
Query!
State/province [102]
0
0
Liverpool
Query!
Country [103]
0
0
United Kingdom
Query!
State/province [103]
0
0
Norwich
Query!
Country [104]
0
0
United Kingdom
Query!
State/province [104]
0
0
Oldham
Query!
Country [105]
0
0
United Kingdom
Query!
State/province [105]
0
0
Peterborough
Query!
Country [106]
0
0
United Kingdom
Query!
State/province [106]
0
0
Randalstown, County Antrim
Query!
Country [107]
0
0
United Kingdom
Query!
State/province [107]
0
0
Spiro Close, Pulborough West Sussex
Query!
Country [108]
0
0
United Kingdom
Query!
State/province [108]
0
0
Wellingborough Northamptonshire
Query!
Country [109]
0
0
United Kingdom
Query!
State/province [109]
0
0
York
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Shionogi
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the long-term safety of naldemedine for the treatment of constipation due to opioid therapy.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01965652
Query!
Trial related presentations / publications
Camilleri M, Hale M, Morlion B, Tack J, Webster L, Wild J. Naldemedine Improves Patient-Reported Outcomes of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain in the COMPOSE Phase 3 Studies. J Pain Res. 2021 Jul 16;14:2179-2189. doi: 10.2147/JPR.S282738. eCollection 2021. Webster LR, Hale ME, Yamada T, Wild JE. A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy. J Pain Res. 2020 Mar 24;13:605-612. doi: 10.2147/JPR.S237833. eCollection 2020. Wild J, Webster L, Yamada T, Hale M. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients >/= 65 Years of Age. Drugs Aging. 2020 Apr;37(4):271-279. doi: 10.1007/s40266-020-00753-2.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Shionogi Clinical Trials Administrator Clinical Support Help Line
Query!
Address
0
0
Shionogi
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01965652
Download to PDF